ZHZhi-Wen Hu

Zhi-Wen Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhi-Wen Hu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Non-Canonical Peptide Self-Assembly for Mitochondria-Specific Cargo Delivery

    by Ziyu Jia, Jian Wen, Shengyi Zhang, Yinghao Ding, Zhimou Yang, Zhi-Wen Hu

    Targeting mitochondria is a promising strategy for precision tumor therapy, yet ligand-free mitochondrial drug delivery remains challenging. Here, we report a minimalist, intrinsically mitochondria-targeting noncanonical tetrapeptide, X-GNNpY, comprising one glycine, two (S)-2-amino-3-(naphthalen-1-yl)-propanoic acid residues (N), and one phosphorylated tyrosine (pY). Without external targeting ligands, X-GNNpY selectively accumulates in tumor-cell mitochondria through enzyme-instructed self-assembly. Conjugating chlorambucil (CLB) yields CLB-GNNpY, which efficiently redirects CLB to mitochondria. CLB-GNNpY exhibits good cellular selectivity, induces mitochondrial stress and immunogenic cell death, promotes M1-like macrophage polarization, and markedly enhances antitumor phagocytosis. This proof-of-concept study establishes noncanonical peptide self-assembly as a ligand-free supramolecular strategy for mitochondrial drug delivery and immune modulation in tumor therapy.

  • Open Access

    CD28‐Targeted Enzyme‐Responsive Conformation‐Switching Peptide Self‐Assembly for Selective T‐Cell Acute Lymphoblastic Leukemia (T‐ALL) Therapy

    by Jun Li, Ziyu Jia, Dekun Li, Zhi‐Wen Hu, Yinghao Ding, Shengyi Zhang, Shengkun Tuo, Zhimou Yang, Huisheng Fu, Ling Wang, et al.

    T‐cell acute lymphoblastic leukemia (T‐ALL) is a highly aggressive hematologic malignancy with limited targeted therapies. CD28, a costimulatory receptor aberrantly overexpressed on T‐ALL cells, presents a promising underexplored therapeutic target. In this study, we developed an enzyme‐responsive self‐assembling peptide, SA p ‐CD28, designed to target CD28 and undergo receptor‐mediated self‐assembly in the tumor microenvironment. Upon dephosphorylation by overexpressed phosphatases, SA p ‐CD28 transitions from an α‐helix to a β‐sheet/β‐turn rich structure, facilitating the formation of nanooligomers that engage CD28 and activate cytotoxic pathways. Transcriptomic and biochemical analyses reveal that SA p ‐CD28 induces a profound dysregulation of CD28 downstream signaling, characterized by the suppression of the PLCγ and Akt pathways. These signaling perturbations lead to oxidative stress and disruption of intracellular calcium homeostasis, resulting in calcium overload, calpain activation, and cytoskeletal collapse. Besides, confocal imaging suggested that the peptide self‐assembly can enter the nucleus and disrupt it. In Jurkat xenograft models, SA p ‐CD28 demonstrated potent antitumor activity, and its combination with cytarabine resulted in near‐complete tumor suppression, highlighting its potential for T‐ALL treatment. This work introduces a CD28‐targeted, enzyme‐activated nanotherapeutic strategy that synergizes biochemical and mechanical mechanisms to selectively eliminate T‐ALL cells. This multi‐mechanistic tumor‐killing strategy can also be extended to inspire therapeutic approaches for other diseases.


  • Tumor‐Targeting Co‐Delivery of T‐Cell Antigen and Camptothecin Guided by Cascade‐Responsive Peptide Self‐Assembly to Reshape Tumor Antigenicity for Cancer Immunotherapy

    by Yinghao Ding, Xueying Zhu, Jian Wen, Junchao Xiong, Shengyi Zhang, Zhimou Yang, Zhi‐Wen Hu

    Antigen presentation deficiency restricted by class I major histocompatibility complex (MHC‐I) causes low antigenicity and antigen escape in tumors, thereby limiting T‐cell immunotherapy outcomes. Here, a combined tumor immunotherapy is developed, in which tumors can present exogenous non‐tumor antigens, and adoptively transferred CD8 + T cells specific for these antigens are re‐targeted to attack tumors. The approach leverages a cascade‐responsive peptide self‐assembly to co‐deliver suitable antigens and the chemotherapeutic drug camptothecin (CPT) to tumors. As a proof‐of‐concept, to re‐target ovalbumin (OVA)‐specific OT‐I CD8 + T cells against tumors, PSA (Nap‐GFFpYE‐ss‐Ag) and CPSA (CPT‐GFFpYE‐ss‐Ag) are constructed, containing an OVA‐derived epitope OVA 257‐264 and/or CPT. The design enables the release of a unique N‐terminal extended OVA 257‐264 and CPT into the cytosol. As a result, the extended antigen is efficiently presented on the tumor surface by MHC‐I, and CPT further enhances this presentation. When combined with adoptively transferred OT‐I CD8 + T cells, the approach effectively facilitates CD8 + T cell infiltration and tumor inhibition. Additionally, CPSA treatment sensitizes immune responses to programmed cell death‐ligand 1 (PD‐L1) blockade, allowing the approach to synergize with an anti‐PD‐L1 antibody for improved tumor eradication.


  • An enzyme-activated and structural transformable supramolecular oncolytic peptide for efficient cancer immunotherapy through systemic administration

    by Zhenghao Zhang, Xingjie Hu, Yuhan Hu, Shengyi Zhang, Yinghao Ding, Xiangyang Zhang, Zhimou Yang, Zhi-Wen Hu


  • Dual-Enzyme-Instructed Peptide Self-Assembly to Boost Immunogenic Cell Death by Coordinating Intracellular Calcium Overload and Chemotherapy

    by Zhenghao Zhang, Yuhan Hu, Yinghao Ding, Xiangyang Zhang, Xiao Dong, Limin Xie, Zhimou Yang, Zhi-Wen Hu

    The concept of immunogenic cell death (ICD) induced by chemotherapy as a potential synergistic modality for cancer immunotherapy has been widely discussed. Unfortunately, most chemotherapeutic agents failed to dictate effective ICD responses due to their defects in inducing potent ICD signaling. Here, we report a dual-enzyme-instructed peptide self-assembly platform of CPMC (CPT-GFFpY-PLGVRK-Caps) that cooperatively utilizes camptothecin (CPT) and capsaicin (Caps) to promote ICD and engage systemic adaptive immunity for tumor rejection. Although CPT and Caps respectively prevent tumor progression by inhibiting type-I DNA topoisomerase and activating transient receptor potential cation channel subfamily V member 1 (TRPV1) for intracellular calcium overload, neither alone effectively stimulates sufficient ICD signaling to meet immunotherapeutic needs. CPMC, sequentially allowing an active Caps derivative of VRK-Caps and CPT to release extracellularly and intracellularly, can synergize two distinct apoptosis pathways stimulated by Caps and CPT to increase tumor immunogenicity and elicit systemic T-cell-based immunity. Consequently, CPMC facilitates the generation of improved tumor-specific cytotoxic T-cell responses and sustained immunological memory, successfully suppressing both primary and distant tumors. Moreover, CPMC can render tumors susceptible to PD-L1 blockade and synergize with an antiprogrammed cell death-ligand 1 (aPDL1) antibody for tumor inhibition. Combining two cancer chemotherapeutic drugs with low ICD-stimulating capacity using a peptide self-assembly strategy was demonstrated to boost ICD responses and potentiate cancer immunotherapy.


  • Enzyme-Instructed Photoactivatable Supramolecular Antigens on Cancer Cell Membranes for Precision-Controlled T-Cell-Based Cancer Immunotherapy

    by Yinghao Ding, Shengyi Zhang, Wei Li, Xiaodong Chen, Jun Li, Xiangyang Zhang, Zhenghao Zhang, Yuanbo Hu, Zhimou Yang, Zhi-Wen Hu, et al.

    Cancer immunotherapies based on cytotoxic CD8+ T lymphocytes (CTLs) are highly promising for cancer treatment. The specific interaction between T-cell receptors and peptide-MHC-I complexes (pMHC-I) on cancer cell membranes critically determines their therapeutic outcomes. However, the lack of appropriate endogenous antigens for MHC-I presentation disables tumor recognition by CTLs. By devising three antigen-loaded self-assembling peptides of pY-K(Ag)-ERGD, pY-K(Ag)-E, and Y-K(Ag)-ERGD to noncovalently generate light-activatable supramolecular antigens at tumor sites in different manners, we report pY-K(Ag)-ERGD as a promising candidate to endow tumor cells with pMHC-I targets on demand. Specifically, pY-K(Ag)-ERGD first generates low-antigenic supramolecular antigens on cancer cell membranes, and a successive light pulse allows antigen payloads to efficiently release from the supramolecular scaffold, directly producing antigenic pMHC-I. Intravenous administration of pY-K(Ag)-ERGD enables light-controlled tumor inhibition when combined with adoptively transferred antigen-specific CTLs. Our strategy is feasible for broadening tumor antigen repertoires for T-cell immunotherapies and advancing precision-controlled T-cell immunotherapies.


  • In Situ Construction of Ferrocene-Containing Membrane-Bound Nanofibers for the Redox Control of Cancer Cell Death and Cancer Therapy

    by Xiangyang Zhang, Yinghao Ding, Zhenghao Zhang, Yiping Ma, Xuan Sun, Ling Wang, Zhimou Yang, Zhi-Wen Hu

    Precise manipulation of cancer cell death by harnessing reactive oxygen species (ROS) is a promising strategy to defeat malignant tumors. However, it is quite difficult to produce active ROS with spatial precision and regulate their biological outcomes. We succeed here in selectively generating short-lived and lipid-reactive hydroxyl radicals (•OH) adjacent to cancer cell membranes, successively eliciting lipid peroxidation and ferroptosis. DiFc-K-pY, a phosphorylated self-assembling precursor that consists of two branched Fc moieties and interacts specifically with epidermal growth factor receptor, can in situ produce membrane-bound nanofibers and enrich ferrocene moieties on cancer cell membranes in response to alkaline phosphatase. Within the acidic tumor microenvironment, DiFc-K-pY nanofibers efficiently convert tumoral H2O2 to active •OH around the target cell membranes via Fenton-like reactions, leading to lipid peroxidation and ferroptosis with good cellular selectivity. Our strategy successfully prevents tumor progression with acceptable biocompatibility through intratumoral administration.


  • Top Cited Papers

    Enzyme-Instructed Peptide Assembly Favored by Preorganization for Cancer Cell Membrane Engineering

    by Yinghao Ding, Debin Zheng, Limin Xie, Xiangyang Zhang, Zhenghao Zhang, Ling Wang, Zhi-Wen Hu, Zhimou Yang

    Innovative methods for engineering cancer cell membranes promise to manipulate cell-cell interactions and boost cell-based cancer therapeutics. Here, we illustrate an in situ approach to selectively modify cancer cell membranes by employing an enzyme-instructed peptide self-assembly (EISA) strategy. Using three phosphopeptides (pY1, pY2, and pY3) targeting the membrane-bound epidermal growth factor receptor (EGFR) and differing in just one phosphorylated tyrosine, we reveal that site-specific phosphorylation patterns in pY1, pY2, and pY3 can distinctly command their preorganization levels, self-assembling kinetics, and spatial distributions of the resultant peptide assemblies in cellulo. Overall, pY1 is the most capable of producing preorganized assemblies and shows the fastest dephosphorylation reaction in the presence of alkaline phosphatase (ALP), as well as the highest binding affinity for EGFR after dephosphorylation. Consequently, pY1 exhibits the greatest capacity to construct stable peptide assemblies on cancer cell membranes with the assistance of both ALP and EGFR. We further use peptide-protein and peptide-peptide co-assembly strategies to apply two types of antigens, namely ovalbumin (OVA) protein and dinitrophenyl (DNP) hapten respectively, on cancer cell membranes. This study demonstrates a very useful technique for the in situ construction of membrane-bound peptide assemblies around cancer cells and implies a versatile strategy to artificially enrich cancer cell membrane components for potential cancer immunotherapy.


  • Less is More: Preorganization Leads to Better Tumor Retention and Therapeutic Efficacy

    by Limin Xie, Yinghao Ding, Yuhan Wang, Xinxin Li, Zhimou Yang, Zhi‐Wen Hu

    Protein preorganization is ubiquitous in nature and enables subtle structural rearrangements and precise function executions, making it an attractive approach for generating functional peptide materials. Here, a phosphorylation‐dependent pre‐organization approach to optimize the therapeutic outcomes of a self‐assembling peptide targeting programmed cell death ligand 1 (PD‐L1) is reported. Upon incorporating the imaging probe cyanine 5.5 (Cy5.5) and therapeutic drug 10‐hydroxycamptothecin (HCPT), three phosphorylated precursors (1P, 2P, and 3P) containing identical peptide sequences with different tyrosine phosphorylation sites are constructed. The presence of a phosphate group can stabilize the self‐assembling peptide in a well‐defined, preorganized state. Moreover, variations in the phosphorylation sites lead to different preorganized secondary structures, dephosphorylation rates, and PD‐L1 binding affinities. Responding to alkaline phosphatase dephosphorylation, subtle structural transformation to more ordered states, an increase in binding affinity against PD‐L1, and rapid cellular internalization are observed. Compared with the unphosphorylated control (0P), the preorganization of 1P, 2P, and 3P can optimize tumor retention and resultant therapeutic performance, of which 3P maximizes the final therapeutic outcomes, leading to a 70.3% tumor inhibition rate. This study highlights the great potential to control the subtle structural transformation and therapeutic effects of self‐assembling peptides by preparing their preorganized entities.


  • Enzyme-instructed self-assembly enabled fluorescence light-up for alkaline phosphatase detection

    by Yiming Zhang, Yinghao Ding, Xinxin Li, Zhenghao Zhang, Xiangyang Zhang, Yumiao Chen, Zhimou Yang, Yang Shi, Zhi-Wen Hu